tiprankstipranks
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk
Company Announcements

Virpax Pharmaceuticals Faces Nasdaq Delisting Risk

Pick the best stocks and maximize your portfolio:

Virpax Pharmaceuticals ( (VRPX) ) just unveiled an update.

Virpax Pharmaceuticals has been notified by Nasdaq of not meeting the minimum bid price requirement of $1.00 for its common stock over the past 30 business days. The company will remain listed as it seeks to correct the deficiency by April 2, 2025, with the possibility of a 180-day extension. If unsuccessful, Virpax may face delisting but is considering measures such as a reverse stock split to regain compliance.

For an in-depth examination of VRPX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskVirpax Pharmaceuticals Welcomes Jay Panis to Board
TipRanks Auto-Generated NewsdeskVirpax Pharmaceuticals Announces Board Member Resignation
Sheryl Sheth3 Penny Stocks to Watch Now, 11/26/24
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App